Arena Pharmaceuticals, Inc. (ARNA) has market cap of $2125.29 million and holds 49.37 million shares outstanding. The stock accomplished trade value at $43.05 with 0.44% and traded volume 193082 shares in recent trading period versus to an average volume of 634.7K. The stock demonstrated move of -1.22% in previous 5 days graph. Its quarterly performance stands with the percentage of 10.02% while its year to date performance showed change of 10.53%.
Arena Pharmaceuticals, Inc. (ARNA) publicized the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH). The global license agreement for ralinepag was announced on November 15, 2018.
Upon closing on January 24, 2019, United Therapeutics paid a non-refundable upfront cash payment of $800 million to Arena. In addition, Arena is eligible to receive potential milestone payments totaling up to $400 million based on the achievement of certain regulatory events and low double-digit tiered royalties on annual net sales of ralinepag.
The stock has monthly performance of 20.39% while its yearly performance remained at 14.25%. Its return on investment (ROI) for the last 12 months was -34.20% and its return on equity (ROE) of -23.80% while return on assets (ROA) is at -19.70%. The Company has an insider ownership of 0.16% and institutional ownership remained 84.40%.